Medtronic Discloses Three Strategic Acquisitions Totaling Over $1.78 Billion in Four Months

　　【Pharmaceutical Network Enterprise NewsRecently, Medtronic announced that it would acquire SPR Therapeutics, a company focused on neuromodulation therapies, for approximately $650 million in cash upfront. The transaction is expected to close within the year.
 

It is reported that through this acquisition, Medtronic aims to strengthen its innovative product portfolio in the field of chronic pain management, providing patients with a broader range of non-pharmacological treatment options. After the completion of the acquisition, SPR's portable neuromodulation platform will be integrated into Medtronic's existing pain solution system. The transaction is expected to close within the year.
 

Notably, since 2026, Medtronic has significantly accelerated its activities in the M&A market. This marks its third major acquisition in nearly four months, with the pace of transactions far exceeding the average frequency of 1-2 medium-sized deals per year over the past three years.
 

Specifically, on April 20, Medtronic announced the completion of its acquisition of CathWorks. Valued at $585 million, the acquisition may also include undisclosed performance-based earn-out payments. CathWorks is dedicated to revolutionizing the diagnosis and treatment of coronary artery disease (CAD). Its FFRangio® system is an AI-driven tool for assessing coronary functional performance.
 

On March 10, Medtronic announced that it had reached a definitive agreement with neurointerventional device company Scientia Vascular to acquire the latter for $5.5 billion (approximately RMB 39 billion). Scientia Vascular focuses on developing neurointerventional devices for the treatment of complex cerebrovascular diseases, with core products including microguidewires, microcatheters, and vascular access platforms. The transaction is expected to be completed in the first half of Medtronic's fiscal year 2027 (May to October 2026).
 

Besides acquisitions, in the first four months of this year, Medtronic actually completed two significant investments. On January 20, Medtronic announced a strategic investment of up to $90 million in Anteris Technologies. According to the terms of the private placement agreement, the investment will be completed by acquiring 16.0% to 19.99% of Anteris's shares. Anteris Technologies is a structural heart device company, with its core product being the DurAVR™ – a single-piece bionic balloon-expandable transcatheter aortic valve (TAVR) that uses the ADAPT™ anti-calcification bovine pericardial tissue technology, designed to mimic the hemodynamics of a healthy aortic valve.
 

In April, Medtronic led the oversubscribed US$100 million Series D financing of Pulnovo Medical. The proceeds from this round of financing will be used for ongoing clinical research and development, global regulatory submissions, international commercialization efforts, and core technology platform construction. At the same time, Medtronic also signed a commercial cooperation agreement with Pulnovo Medical. This agreement aims to fully leverage the commercial synergies between Pulnovo Medical and Medtronic, utilizing Medtronic's unique and extensive global commercialization capabilities to jointly promote the widespread application of innovative therapies.
 

Different from the past pursuit of scale effect through "elephant mergers," Medtronic's M&A activities in 2026 are characterized by "small incisions, deep positioning, and quick returns." The industry believes that this marks a shift in Medtronic's strategic thinking—from relying on a large product line for "passive defense" to proactively opening up new battlegrounds through precise acquisitions. By implementing targeted "bolt-on acquisitions," Medtronic is swiftly incorporating cutting-edge technologies such as AI diagnostics, neural pathways, and pain management into its portfolio. In the medium to long term, these acquired assets are expected to collectively form Medtronic's "second growth curve."
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.